Last reviewed · How we verify
NCT04185766
Prevention of Hypoglycaemia by Oral 40% Destrogel
NA trial testing Administration of a placebo solution (0.5 ml / kg) in Hypoglycaemia Neonatal in 172 participants. Completed in 5 May 2019.
5 May 2019
Quick facts
| Lead sponsor | Fondazione Poliambulanza Istituto Ospedaliero |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 172 |
| Start date | 23 November 2018 |
| Primary completion | 5 May 2019 |
| Estimated completion | 5 May 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Administration of a placebo solution (0.5 ml / kg)
- Administration of a placebo solution (1 ml / kg)
- Administration of 40% glucose in gel (0.5 ml / Kg)
- Administration of 40% glucose in gel 1 ml / Kg)
Conditions studied
- Hypoglycaemia Neonatal — all drugs for Hypoglycaemia Neonatal →
Sponsor
Fondazione Poliambulanza Istituto Ospedaliero — full company profile →
Who can join
Adults 34 Weeks to 42 Weeks, any sex, with Hypoglycaemia Neonatal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neonatal hypoglycemia understood as a reduction in plasma glucose can result in long-term neurological damage. Serious monitoring of neonatal blood glucose is indicated in patients at risk of hypoglycemia. Glycaemic monitoring in the newborn at risk should be started not before of the two hours of life, in fact at birth the neonatal blood glucose values are very low because they are conditioned by the metabolic activity of the foetus in the intrauterine phase, while later these values rise again until arrive at similar values to the adult within 48-72 hours. In recent years, various research groups have been evaluating the possibility of arriving at non-pharmacological prophylaxis of hypoglycemia. In particular, the Hegarty group has set up a protocol that uses dextrose gel at 40% in the risk categories that could reduce the number of hypoglycemia cases and consequently of painful procedures. In 2013 Harris et al. conducted a study to evaluate the failure rate in the treatment of hypoglycaemia in a sample of 242 newborns assigned in the 1:1 ratio to case or control group. The cases were treated with 40% dextrose in gel with a concentration of 200 mg/kg while the controls with a placebo solution. Newborns of both groups were encouraged to feed but if the feeding was insufficient, it was administered breast milk or formula milk through a syringe. Treated group showed a failure rate in reversion of lower hypoglycaemia compared to controls (14% vs 24%, RR = 0.57 (0.33-0.98), p = 0.04). Hegarty et al conducted a clinical trial in which 416 newborns were randomized and assigned to one of 4 types of treatment: dextrose 40% in gel in a single-dose (200 mg/kg) or double-dose (400 mg/kg ) 1 hour after birth or followed by 3 additional doses of dextrose (200 mg/kg) in the first 12 hours. Blood glucose was measured at 2 hours from birth then every 2-4 hours for the first 12 hours of life. The incidence of hypoglycaemia was lower in the treated than in the control group treated with a placebo solution (41% vs 52%, RR = 0.79 (0.64-0.98), p = 0.03). The group of newborns treated with a single administration of gel at a concentration of 200 mg/kg showed a greater reduction in the incidence of hypoglycaemia compared to the other types of treatment (38% vs 56%, RR = 0.66 (0.47-0.99), p=0.04)
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Strategies to improve neurodevelopmental outcomes in babies at risk of neonatal hypoglycaemia.
Alsweiler JM, Harris DL, Harding JE, McKinlay CJD. · · 2021 · cited 23× · PMID 33836151 · DOI 10.1016/s2352-4642(20)30387-4 -
Oral dextrose gel to prevent hypoglycaemia in at-risk neonates.
Edwards T, Liu G, Hegarty JE, Crowther CA, et al · · 2021 · cited 21× · PMID 33998668 · DOI 10.1002/14651858.cd012152.pub3 -
Oral dextrose gel to prevent hypoglycaemia in at-risk neonates.
Roberts L, Lin L, Alsweiler J, Edwards T, et al · · 2023 · cited 12× · PMID 38014716 · DOI 10.1002/14651858.cd012152.pub4
Verify or expand the search:
- PubMed search for NCT04185766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondazione Poliambulanza Istituto Ospedaliero trials
Trials by the same sponsor.
- NCT07111715 — Comparison Between Artificial Intelligence and Standard Reading to Investigate Suspected Crohn Disease: the SCAI STUDY · recruiting
- NCT06068023 — The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. · recruiting
- NCT05475041 — Perioperative Outcomes of Simultaneous Colorectal and Liver Resections · completed
- NCT05478889 — Minimally Invasive Pancreatoduodenectomy for Distal Cholangiocarcinoma · completed
- NCT05862948 — Accuracy of Endo-aid in Consecutive Patients Referred for Colonoscopy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04185766 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Poliambulanza Istituto Ospedaliero
- Last refreshed: 4 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04185766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing